Even though there are not yet reliable biomarkers based on the detection of STMN2 or UNC13A cryptic exons, development of these approaches may have ground-breaking implications for subcategorization of patients and the development of personalized therapeutics in TDP-43 proteinopathies, including Alzheimer’s disease. Here, STMN2 is linked to early-onset autosomal dominant Alzheimer disease.